Weili Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Weili Li has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jiayue Ding
Department of Neurology, Tianjin Medical University General Hospital, China (J.D.).
5 shared publications - Xunming Ji
Capital Medical University
4 shared publications Zhiying Chen
Department of Neurology, Jiujiang University Affiliated Hospital, China (Z.C.).
4 shared publications- Ju Han
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
3 shared publications - Shuhua Yuan
Capital Medical University
3 shared publications - Zhifeng Qi
Department of Neurology, Cerebrovascular Diseases Research Institute Xuanwu Hospital of Capital Medical University Beijing China
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 2004605
Editorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
Chronic large-vessel occlusion is best understood not as a static angiographic finding but as a dynamic cerebrovascular state in which anatomy, collateral adaptation, hemodynamic reserve, tissue vulnerability, and treatment strategy interact over time. This distinction matters clinically. Hemodynamic impairment has been associated with recurrent ischemic risk in carotid occlusive disease (1), yet randomized trials of extracranial-intracranial bypass, including COSS and CMOSS, have not demonstrated an overall benefit over medical therapy in selected patients with symptomatic carotid or middle cerebral artery occlusion (2,3). Meanwhile, advances in endovascular recanalization have renewed interest in carefully selected patients with chronic occlusion, although the evidence remains largely observational (4). These apparently conflicting observations point to a central challenge: the presence of an occluded artery alone is insufficient to identify who will deteriorate, who may benefit from revascularization, and who may be harmed by intervention. Patients with similar angiographic lesions may have markedly different clinical trajectories depending on collateral sufficiency and residual perfusion. Accordingly, diagnosis should move beyond defining the site and length of occlusion toward characterizing its physiological consequences and the viability of the threatened vascular territory.The contributions to this Research Topic, taken together, extend beyond chronic occlusion itself and support a more useful continuum-based framework for large-vessel occlusive disease-from vascular remodeling and collateral compensation, through patient selection and revascularization, to procedural execution and post-reperfusion recovery. Collateral biology is a logical starting point. Li et al. review postoperative collateral formation in moyamoya disease, a prototypical chronic progressive steno-occlusive arteriopathy, and highlight the interplay of genetic susceptibility, angiogenic signaling, cellular mechanisms, and clinical factors. Their synthesis reinforces an important concept: successful revascularization depends not only on restoring a conduit for blood flow, but also on the biological capacity of the cerebral circulation to adapt. This is consistent with contemporary views of moyamoya disease as a heterogeneous disorder in which mechanisms, hemodynamics, and response to revascularization vary substantially across patients (5). For chronic large-vessel occlusion more broadly, anatomical severity should therefore be interpreted together with collateral status, perfusion, and cerebrovascular reserve rather than in isolation.A second theme is the transition from a binary question-whether to revascularize-to a more precise question: which patient, which lesion, and which strategy? Qureshi et al. explored a potentially higher-risk subgroup of patients with extracranial vertebral artery stenosis treated soon after ischemic stroke. The primary vertebrobasilar stroke/death endpoint did not reach conventional statistical significance, although exploratory outcomes favored stenting, appropriately framing the findings as hypothesis-generating rather than definitive. This nuance is important because pooled randomized evidence has continued to show uncertainty regarding the clinical benefit of vertebral artery stenting (6) We therefore view the central message of this Research Topic as one of precision rather than procedural expansion. Future studies should standardize definitions of chronicity and technical success, quantify hemodynamic failure and collateral capacity, distinguish embolic from lowflow mechanisms, and prospectively validate multimodal models that integrate vascular anatomy, perfusion, clinical phenotype, and biological markers. Most importantly, chronic occlusionspecific evidence still requires prospective multicenter cohorts and randomized studies capable of identifying treatment-responsive subgroups. The goal is not simply to reopen an artery. It is to determine when restoring flow can be achieved safely, for the right mechanism and the right patient, and translated into durable neurological benefit.
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 2004605
Open AccessEditorial: Chronic large-vessel occlusion in cerebrovascular disease: pathophysiology, diagnosis, and therapeutic advances
Chronic large-vessel occlusion is best understood not as a static angiographic finding but as a dynamic cerebrovascular state in which anatomy, collateral adaptation, hemodynamic reserve, tissue vulnerability, and treatment strategy interact over time. This distinction matters clinically. Hemodynamic impairment has been associated with recurrent ischemic risk in carotid occlusive disease (1), yet randomized trials of extracranial-intracranial bypass, including COSS and CMOSS, have not demonstrated an overall benefit over medical therapy in selected patients with symptomatic carotid or middle cerebral artery occlusion (2,3). Meanwhile, advances in endovascular recanalization have renewed interest in carefully selected patients with chronic occlusion, although the evidence remains largely observational (4). These apparently conflicting observations point to a central challenge: the presence of an occluded artery alone is insufficient to identify who will deteriorate, who may benefit from revascularization, and who may be harmed by intervention. Patients with similar angiographic lesions may have markedly different clinical trajectories depending on collateral sufficiency and residual perfusion. Accordingly, diagnosis should move beyond defining the site and length of occlusion toward characterizing its physiological consequences and the viability of the threatened vascular territory.The contributions to this Research Topic, taken together, extend beyond chronic occlusion itself and support a more useful continuum-based framework for large-vessel occlusive disease-from vascular remodeling and collateral compensation, through patient selection and revascularization, to procedural execution and post-reperfusion recovery. Collateral biology is a logical starting point. Li et al. review postoperative collateral formation in moyamoya disease, a prototypical chronic progressive steno-occlusive arteriopathy, and highlight the interplay of genetic susceptibility, angiogenic signaling, cellular mechanisms, and clinical factors. Their synthesis reinforces an important concept: successful revascularization depends not only on restoring a conduit for blood flow, but also on the biological capacity of the cerebral circulation to adapt. This is consistent with contemporary views of moyamoya disease as a heterogeneous disorder in which mechanisms, hemodynamics, and response to revascularization vary substantially across patients (5). For chronic large-vessel occlusion more broadly, anatomical severity should therefore be interpreted together with collateral status, perfusion, and cerebrovascular reserve rather than in isolation.A second theme is the transition from a binary question-whether to revascularize-to a more precise question: which patient, which lesion, and which strategy? Qureshi et al. explored a potentially higher-risk subgroup of patients with extracranial vertebral artery stenosis treated soon after ischemic stroke. The primary vertebrobasilar stroke/death endpoint did not reach conventional statistical significance, although exploratory outcomes favored stenting, appropriately framing the findings as hypothesis-generating rather than definitive. This nuance is important because pooled randomized evidence has continued to show uncertainty regarding the clinical benefit of vertebral artery stenting (6) We therefore view the central message of this Research Topic as one of precision rather than procedural expansion. Future studies should standardize definitions of chronicity and technical success, quantify hemodynamic failure and collateral capacity, distinguish embolic from lowflow mechanisms, and prospectively validate multimodal models that integrate vascular anatomy, perfusion, clinical phenotype, and biological markers. Most importantly, chronic occlusionspecific evidence still requires prospective multicenter cohorts and randomized studies capable of identifying treatment-responsive subgroups. The goal is not simply to reopen an artery. It is to determine when restoring flow can be achieved safely, for the right mechanism and the right patient, and translated into durable neurological benefit.
- 27 October 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Endovascular recanalization versus medical therapy for symptomatic non-acute intracranial artery occlusion: a systematic review and meta-analysis
Background The benefit-risk profile of endovascular recanalization for symptomatic intracranial arterial occlusion beyond 24 hours remains uncertain across clinically distinct presentations. Methods We systematically reviewed comparative studies of endovascular recanalization plus best medical therapy (BMT) versus BMT alone in adults treated >24 hours after symptom onset or last known well. Four databases were searched through July 15, 2026. Random-effects meta-analyses separated adjusted from unadjusted estimates; subgroup analyses examined vascular territory, clinical phenotype, and occlusion etiology. Results 15 observational studies involving 2724 participants were included; no eligible randomized trials were identified. Endovascular treatment was associated with higher odds of 90-day functional independence in crude analyses (OR 1.94, 95% CI 1.15 to 3.25, I²=75%) and in seven studies reporting comparable adjusted ORs (aOR 3.99, 95% CI 2.87 to 5.55, I²=0%). Symptomatic intracranial hemorrhage was more frequent after endovascular treatment (aOR 9.54, 95% CI 3.78 to 24.07, I²=0%). Adjusted 90-day mortality was uncertain (aOR 0.63, 95% CI 0.32 to 1.26). Two small studies suggested fewer recurrent strokes (OR 0.25, 95% CI 0.10 to 0.65). Subgroup analyses showed no statistically significant interactions, but were underpowered. Certainty was low or very low. Conclusions Low-certainty evidence suggests that delayed endovascular recanalization may improve functional independence but increases symptomatic intracranial hemorrhage in selected patients. Clinical heterogeneity and residual confounding preclude support for routine treatment and justify phenotype-specific randomized trials.
- 27 October 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Endovascular recanalization versus medical therapy for symptomatic non-acute intracranial artery occlusion: a systematic review and meta-analysis
Background The benefit-risk profile of endovascular recanalization for symptomatic intracranial arterial occlusion beyond 24 hours remains uncertain across clinically distinct presentations. Methods We systematically reviewed comparative studies of endovascular recanalization plus best medical therapy (BMT) versus BMT alone in adults treated >24 hours after symptom onset or last known well. Four databases were searched through July 15, 2026. Random-effects meta-analyses separated adjusted from unadjusted estimates; subgroup analyses examined vascular territory, clinical phenotype, and occlusion etiology. Results 15 observational studies involving 2724 participants were included; no eligible randomized trials were identified. Endovascular treatment was associated with higher odds of 90-day functional independence in crude analyses (OR 1.94, 95% CI 1.15 to 3.25, I²=75%) and in seven studies reporting comparable adjusted ORs (aOR 3.99, 95% CI 2.87 to 5.55, I²=0%). Symptomatic intracranial hemorrhage was more frequent after endovascular treatment (aOR 9.54, 95% CI 3.78 to 24.07, I²=0%). Adjusted 90-day mortality was uncertain (aOR 0.63, 95% CI 0.32 to 1.26). Two small studies suggested fewer recurrent strokes (OR 0.25, 95% CI 0.10 to 0.65). Subgroup analyses showed no statistically significant interactions, but were underpowered. Certainty was low or very low. Conclusions Low-certainty evidence suggests that delayed endovascular recanalization may improve functional independence but increases symptomatic intracranial hemorrhage in selected patients. Clinical heterogeneity and residual confounding preclude support for routine treatment and justify phenotype-specific randomized trials.
- 1 August 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2265-2275
Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial
BACKGROUND: Normobaric hyperoxia (NBO) is a simple neuroprotective strategy that may augment endovascular thrombectomy (EVT) in acute ischemic stroke. We evaluated the safety and preliminary efficacy of NBO plus EVT in patients with large-vessel occlusion presenting 6 to 24 hours after onset. METHODS: In this phase IIb, randomized, assessor-blinded, controlled trial conducted at 2 academic comprehensive stroke centers in China, patients aged ≥18 years with anterior circulation large-vessel occlusion presenting 6 to 24 hours after acute ischemic stroke onset were assigned 1:1 to EVT+NBO or EVT alone. The NBO group received 100% oxygen via a face mask at 10 L/min for 4 hours, starting before recanalization. The primary end point was early neurological improvement (≥30% reduction in the National Institutes of Health Stroke Scale score at 24 hours). Primary analyses used adjusted regression models controlling for prespecified prognostic covariates. Secondary end points included infarct volume at 24 to 48 hours and the modified Rankin Scale score at 90 days. Safety outcomes were mortality, intracranial hemorrhage, and symptomatic intracranial hemorrhage. Analyses followed the intention-to-treat principle. Early neurological improvement was analyzed using an adjusted binomial regression model, and the 90-day modified Rankin Scale shift was analyzed using an adjusted ordinal logistic regression model, controlling for age, sex, intravenous thrombolysis, and occlusion site. RESULTS: Between October 2021 and October 2023, 324 patients were screened, and 120 were randomly assigned to NBO+EVT or EVT alone (60 patients per group; intention-to-treat population). The median baseline National Institutes of Health Stroke Scale score was 12 (interquartile range [IQR], 8–15) in the NBO+EVT group and 12 (IQR, 9–16) in the EVT-alone group. The median time from stroke onset to randomization was 10.0 hours (IQR, 7.0–14.4) and 9.9 hours (IQR, 8.4–14.8), respectively. The EVT+NBO group demonstrated a significantly higher rate of early neurological improvement compared with EVT alone (35% versus 19%; adjusted odds ratio, 2.86 [95% CI, 1.12–7.45]). The median infarct volume at 24 to 48 hours was significantly smaller in the EVT+NBO group (20.5 [IQR, 13.6–31.8] mL versus 32.3 [IQR, 22.7–44.5] mL; P =0.001). At 90 days, the modified Rankin Scale distribution numerically favored NBO+EVT but was not statistically significant (median modified Rankin Scale, 2 [IQR, 1–3] versus 3 [IQR, 1–4]; adjusted common odds ratio, 1.52 [95% CI, 0.87–2.63]). Mortality, symptomatic intracranial hemorrhage, early neurological deterioration, and recurrent stroke did not differ between groups. CONCLUSIONS: In patients with acute ischemic stroke treated 6 to 24 hours after onset, adjunctive NBO with EVT was safe and improved early neurological outcomes and infarct volume, supporting further evaluation in larger trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05128422.
- 1 August 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2265-2275
Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial
BACKGROUND: Normobaric hyperoxia (NBO) is a simple neuroprotective strategy that may augment endovascular thrombectomy (EVT) in acute ischemic stroke. We evaluated the safety and preliminary efficacy of NBO plus EVT in patients with large-vessel occlusion presenting 6 to 24 hours after onset. METHODS: In this phase IIb, randomized, assessor-blinded, controlled trial conducted at 2 academic comprehensive stroke centers in China, patients aged ≥18 years with anterior circulation large-vessel occlusion presenting 6 to 24 hours after acute ischemic stroke onset were assigned 1:1 to EVT+NBO or EVT alone. The NBO group received 100% oxygen via a face mask at 10 L/min for 4 hours, starting before recanalization. The primary end point was early neurological improvement (≥30% reduction in the National Institutes of Health Stroke Scale score at 24 hours). Primary analyses used adjusted regression models controlling for prespecified prognostic covariates. Secondary end points included infarct volume at 24 to 48 hours and the modified Rankin Scale score at 90 days. Safety outcomes were mortality, intracranial hemorrhage, and symptomatic intracranial hemorrhage. Analyses followed the intention-to-treat principle. Early neurological improvement was analyzed using an adjusted binomial regression model, and the 90-day modified Rankin Scale shift was analyzed using an adjusted ordinal logistic regression model, controlling for age, sex, intravenous thrombolysis, and occlusion site. RESULTS: Between October 2021 and October 2023, 324 patients were screened, and 120 were randomly assigned to NBO+EVT or EVT alone (60 patients per group; intention-to-treat population). The median baseline National Institutes of Health Stroke Scale score was 12 (interquartile range [IQR], 8–15) in the NBO+EVT group and 12 (IQR, 9–16) in the EVT-alone group. The median time from stroke onset to randomization was 10.0 hours (IQR, 7.0–14.4) and 9.9 hours (IQR, 8.4–14.8), respectively. The EVT+NBO group demonstrated a significantly higher rate of early neurological improvement compared with EVT alone (35% versus 19%; adjusted odds ratio, 2.86 [95% CI, 1.12–7.45]). The median infarct volume at 24 to 48 hours was significantly smaller in the EVT+NBO group (20.5 [IQR, 13.6–31.8] mL versus 32.3 [IQR, 22.7–44.5] mL; P =0.001). At 90 days, the modified Rankin Scale distribution numerically favored NBO+EVT but was not statistically significant (median modified Rankin Scale, 2 [IQR, 1–3] versus 3 [IQR, 1–4]; adjusted common odds ratio, 1.52 [95% CI, 0.87–2.63]). Mortality, symptomatic intracranial hemorrhage, early neurological deterioration, and recurrent stroke did not differ between groups. CONCLUSIONS: In patients with acute ischemic stroke treated 6 to 24 hours after onset, adjunctive NBO with EVT was safe and improved early neurological outcomes and infarct volume, supporting further evaluation in larger trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05128422.
- Open Access
- 9 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70960
Neuroprotective Effects of Phenothiazines on Acute Ischemic Stroke
Background: Standard therapeutic strategies for acute ischemic stroke (AIS) include endovascular mechanical thrombectomy, intravenous thrombolysis, bridging therapy, and conventional conservative treatment. Despite the implementation of standardized treatments, nearly half of patients still experience significant motor or speech dysfunction, severely impacting their quality of life. Consequently, there is a pressing need for effective neuroprotective adjunctive therapies to further improve functional outcomes and prognosis. Phenothiazines, primarily chlorpromazine and promethazine (C + P), have been proposed as potential neuroprotective agents. Preclinical evidence suggests that phenothiazines may induce mild hypothermic responses, exert anti‐inflammatory effects, and promote a hypometabolic state, thereby potentially contributing to improved neurological outcomes. Methods: We reviewed and synthesized the mechanisms underlying the neuroprotective effects of phenothiazines, with a particular focus on C + P. Results: This review highlights the neuroprotective mechanisms of phenothiazines related to mild hypothermia, anti‐inflammation, and metabolic reduction, along with relevant preclinical and clinical evidence. We also compare the distinct mechanisms of action between C + P and conventional anesthetic sedatives and draw partial comparisons with natural hibernation. Our findings reveal that C + P possesses unique features and advantages in neuroprotection, particularly regarding metabolic suppression and hypothermia. Conclusions: This review explores the adjunctive role of phenothiazines following AIS and elucidates their modulatory mechanisms, which may exert neuroprotective effects through multiple pathways and potentially improve AIS outcomes. This approach may facilitate the identification of novel specific targets for conventional drugs, thereby offering a new perspective on addressing the challenges associated with AIS.
- 9 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70960
Open AccessNeuroprotective Effects of Phenothiazines on Acute Ischemic Stroke
Background: Standard therapeutic strategies for acute ischemic stroke (AIS) include endovascular mechanical thrombectomy, intravenous thrombolysis, bridging therapy, and conventional conservative treatment. Despite the implementation of standardized treatments, nearly half of patients still experience significant motor or speech dysfunction, severely impacting their quality of life. Consequently, there is a pressing need for effective neuroprotective adjunctive therapies to further improve functional outcomes and prognosis. Phenothiazines, primarily chlorpromazine and promethazine (C + P), have been proposed as potential neuroprotective agents. Preclinical evidence suggests that phenothiazines may induce mild hypothermic responses, exert anti‐inflammatory effects, and promote a hypometabolic state, thereby potentially contributing to improved neurological outcomes. Methods: We reviewed and synthesized the mechanisms underlying the neuroprotective effects of phenothiazines, with a particular focus on C + P. Results: This review highlights the neuroprotective mechanisms of phenothiazines related to mild hypothermia, anti‐inflammation, and metabolic reduction, along with relevant preclinical and clinical evidence. We also compare the distinct mechanisms of action between C + P and conventional anesthetic sedatives and draw partial comparisons with natural hibernation. Our findings reveal that C + P possesses unique features and advantages in neuroprotection, particularly regarding metabolic suppression and hypothermia. Conclusions: This review explores the adjunctive role of phenothiazines following AIS and elucidates their modulatory mechanisms, which may exert neuroprotective effects through multiple pathways and potentially improve AIS outcomes. This approach may facilitate the identification of novel specific targets for conventional drugs, thereby offering a new perspective on addressing the challenges associated with AIS.
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e041825
Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation
Background: Inflammatory response is an important pathological and physiological mechanism in the occurrence and development of acute ischemic stroke. This study investigated the effects of normobaric hyperoxia on the inflammatory response in acute ischemic stroke and explored the role of inflammation in stroke‐induced brain injury. Methods: This secondary analysis of the OPENS (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, included 86 acute ischemic stroke patients with anterior circulation large vessel occlusion: 43 received normobaric hyperoxia (10 L/min, 100% oxygen for 4 hours) with endovascular thrombectomy, and 43 received endovascular thrombectomy alone. Inflammatory markers were measured at different time points (admission, 24 hours, 7 days), and National Institutes of Health Stroke Scale score and cerebral infarction volume were also recorded. The main outcome measures were serum CRP (C‐reactive protein) levels, peripheral blood leukocyte count, neutrophil count, and neutrophil‐to‐lymphocyte ratio. Correlation analysis was used to analyze the relationship between inflammatory markers and stroke. Results: The results showed that the normobaric hyperoxia group had significantly lower levels of inflammatory markers compared with the control group at 24 hours ( P <0.05). Early correlation analysis (within 24 hours) showed a significant positive association between 24‐hour inflammatory marker levels and early neurological function scores (National Institutes of Health Stroke Scale) as well as early infarct volume (assessed at 24–48 hours). Conclusions: Normobaric hyperoxia attenuates early postthrombectomy inflammation, as evidenced by reduced CRP, neutrophil counts, and neutrophil‐to‐lymphocyte ratio. These inflammation markers were significantly associated with acute stroke severity and infarct volume. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03620370.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e041825
Open AccessNormobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation
Background: Inflammatory response is an important pathological and physiological mechanism in the occurrence and development of acute ischemic stroke. This study investigated the effects of normobaric hyperoxia on the inflammatory response in acute ischemic stroke and explored the role of inflammation in stroke‐induced brain injury. Methods: This secondary analysis of the OPENS (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, included 86 acute ischemic stroke patients with anterior circulation large vessel occlusion: 43 received normobaric hyperoxia (10 L/min, 100% oxygen for 4 hours) with endovascular thrombectomy, and 43 received endovascular thrombectomy alone. Inflammatory markers were measured at different time points (admission, 24 hours, 7 days), and National Institutes of Health Stroke Scale score and cerebral infarction volume were also recorded. The main outcome measures were serum CRP (C‐reactive protein) levels, peripheral blood leukocyte count, neutrophil count, and neutrophil‐to‐lymphocyte ratio. Correlation analysis was used to analyze the relationship between inflammatory markers and stroke. Results: The results showed that the normobaric hyperoxia group had significantly lower levels of inflammatory markers compared with the control group at 24 hours ( P <0.05). Early correlation analysis (within 24 hours) showed a significant positive association between 24‐hour inflammatory marker levels and early neurological function scores (National Institutes of Health Stroke Scale) as well as early infarct volume (assessed at 24–48 hours). Conclusions: Normobaric hyperoxia attenuates early postthrombectomy inflammation, as evidenced by reduced CRP, neutrophil counts, and neutrophil‐to‐lymphocyte ratio. These inflammation markers were significantly associated with acute stroke severity and infarct volume. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03620370.
- Open Access
- 24 February 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (2) , e70806
Oxygen Therapy for Intracranial Hemorrhage
Aims: Intracranial hemorrhage (ICH) is a severe cerebrovascular disease with a high mortality rate that impairs patient well‐being and quality of life. Oxygen therapies, including hyperbaric hyperoxia (HBO) and normobaric hyperoxia (NBO), have attracted widespread attention as potential adjuvant treatments because of their neuroprotective effects. This review aimed to summarize the current literature addressing the neuroprotective mechanisms of oxygen therapy in ICH, as well as its effectiveness and safety in patients with ICH. Methods: We systematically searched multiple literature databases including PubMed, Embase, and Cochrane for publications containing specified keywords and published prior to November 2025. The references were thoroughly reviewed to identify other articles that may have been missed in our search. Results: A total of 38 articles were included in this study. Among them, 20 mainly studied the mechanism of oxygen therapy after ICH, eight mainly investigated the effects of oxygen therapy in patients with ICH, and 10 primarily analyzed the safety of oxygen therapy in patients with ICH. The experimental results showed that the treatment mechanism of HBO mainly involves reducing cerebral vasospasm, promoting angiogenesis, inhibiting inflammatory responses, and improving aerobic energy metabolism, whereas NBO mainly protects the blood–brain barrier (BBB), reduces cerebral edema and hemispheric swelling, mitigates acute inflammation, inhibits oxidative stress and neuronal cell death, and enhances aerobic metabolism. Clinical trials have shown that oxygen therapy can improve neurological function recovery and long‐term prognosis in patients with ICH, as reflected by better scores in some indicators and lower mortality rates; however, oxygen therapy also has controversial and potential risks. Excessive oxygen supply may lead to adverse reactions, and hyperoxia may negatively impact patients with ICH. An appropriate treatment plan should be formulated for the clinical application of oxygen therapy. Conclusion: Oxygen therapy shows potential in ICH treatment through multiple mechanisms; however, its safety and optimal regimen require further large‐scale randomized controlled trials to balance the benefits and risks and optimize its application strategies.
- 24 February 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (2) , e70806
Open AccessOxygen Therapy for Intracranial Hemorrhage
Aims: Intracranial hemorrhage (ICH) is a severe cerebrovascular disease with a high mortality rate that impairs patient well‐being and quality of life. Oxygen therapies, including hyperbaric hyperoxia (HBO) and normobaric hyperoxia (NBO), have attracted widespread attention as potential adjuvant treatments because of their neuroprotective effects. This review aimed to summarize the current literature addressing the neuroprotective mechanisms of oxygen therapy in ICH, as well as its effectiveness and safety in patients with ICH. Methods: We systematically searched multiple literature databases including PubMed, Embase, and Cochrane for publications containing specified keywords and published prior to November 2025. The references were thoroughly reviewed to identify other articles that may have been missed in our search. Results: A total of 38 articles were included in this study. Among them, 20 mainly studied the mechanism of oxygen therapy after ICH, eight mainly investigated the effects of oxygen therapy in patients with ICH, and 10 primarily analyzed the safety of oxygen therapy in patients with ICH. The experimental results showed that the treatment mechanism of HBO mainly involves reducing cerebral vasospasm, promoting angiogenesis, inhibiting inflammatory responses, and improving aerobic energy metabolism, whereas NBO mainly protects the blood–brain barrier (BBB), reduces cerebral edema and hemispheric swelling, mitigates acute inflammation, inhibits oxidative stress and neuronal cell death, and enhances aerobic metabolism. Clinical trials have shown that oxygen therapy can improve neurological function recovery and long‐term prognosis in patients with ICH, as reflected by better scores in some indicators and lower mortality rates; however, oxygen therapy also has controversial and potential risks. Excessive oxygen supply may lead to adverse reactions, and hyperoxia may negatively impact patients with ICH. An appropriate treatment plan should be formulated for the clinical application of oxygen therapy. Conclusion: Oxygen therapy shows potential in ICH treatment through multiple mechanisms; however, its safety and optimal regimen require further large‐scale randomized controlled trials to balance the benefits and risks and optimize its application strategies.
- 11 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120678
Endovascular treatment for non-acute intracranial vertebrobasilar artery occlusion in Chinese elderly: Efficacy and safety outcomes
- 11 February 2026
- Published by Elsevier in Atherosclerosis
- Vol. 415, 120678
Endovascular treatment for non-acute intracranial vertebrobasilar artery occlusion in Chinese elderly: Efficacy and safety outcomes
- 18 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e405-e411
Vessel wall MRI evaluation for the safety of endovascular recanalization of non-acute intracranial anterior circulation artery occlusions
Background Vessel wall MRI (VWMRI) can reveal the morphological features of intracranial artery occlusion (ICAO). This study aimed to investigate the imaging features of ICAO on VWMRI and explore their correlation with perioperative complications of endovascular recanalization for non-acute ICAO. Methods The study retrospectively included consecutive patients with recurrent ischemic stroke due to non-acute ICAO in the anterior circulation who underwent preoperative VWMRI evaluation and endovascular recanalization. Perioperative complications included ischemic and hemorrhagic strokes within 30 days after operation. Imaging features of the occluded segments were evaluated on precontrast and post-contrast VWMRI, including occlusion length and site, vessel wall area, signal intensity, angle, and shape of the occluded segment. The associations between the clinical and imaging features and perioperative complications were examined. Results One hundred and four patients were included in the analysis, of whom 22.1% (23/104) had perioperative complications. After adjusting for multiple confounding variables, four imaging risk factors were identified that were independently associated with perioperative complications, that is, the angle between the occluded and pre-occluded artery segments (OR 11.60, 95% CI 2.73 to 49.29), occluded artery segment shape (OR 13.07, 95% CI 2.82 to 60.67), vessel wall collapse before occlusion (OR 2.91, 95% CI 0.96 to 8.77), and post-contrast mean signal intensity ratio at the ¼ point of the occluded artery segment Conclusions VWMRI may be helpful to select patients with non-acute ICAO who are suitable for endovascular recanalization.
- 18 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e405-e411
Vessel wall MRI evaluation for the safety of endovascular recanalization of non-acute intracranial anterior circulation artery occlusions
Background Vessel wall MRI (VWMRI) can reveal the morphological features of intracranial artery occlusion (ICAO). This study aimed to investigate the imaging features of ICAO on VWMRI and explore their correlation with perioperative complications of endovascular recanalization for non-acute ICAO. Methods The study retrospectively included consecutive patients with recurrent ischemic stroke due to non-acute ICAO in the anterior circulation who underwent preoperative VWMRI evaluation and endovascular recanalization. Perioperative complications included ischemic and hemorrhagic strokes within 30 days after operation. Imaging features of the occluded segments were evaluated on precontrast and post-contrast VWMRI, including occlusion length and site, vessel wall area, signal intensity, angle, and shape of the occluded segment. The associations between the clinical and imaging features and perioperative complications were examined. Results One hundred and four patients were included in the analysis, of whom 22.1% (23/104) had perioperative complications. After adjusting for multiple confounding variables, four imaging risk factors were identified that were independently associated with perioperative complications, that is, the angle between the occluded and pre-occluded artery segments (OR 11.60, 95% CI 2.73 to 49.29), occluded artery segment shape (OR 13.07, 95% CI 2.82 to 60.67), vessel wall collapse before occlusion (OR 2.91, 95% CI 0.96 to 8.77), and post-contrast mean signal intensity ratio at the ¼ point of the occluded artery segment Conclusions VWMRI may be helpful to select patients with non-acute ICAO who are suitable for endovascular recanalization.
- Open Access
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Enhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Open AccessEnhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.